Navigation Links
Anthera Pharmaceuticals Reports 2013 First Quarter Financial Results
Date:5/13/2013

of lower loss from operations and higher common shares outstanding due to a public offering of shares of the Company's common stock in the first quarter of 2013, pursuant to which the Company raised net proceeds of approximately $42.7 million through the issuance of 69,696,970 shares of common stock.

As of March 31, 2013, the Company had cash, cash equivalents and short-term investments of $54.4 million, as compared to $24.8 million at December 31, 2012.  The increase in cash was primarily attributable of a public offering of shares of the Company's common stock in first quarter of 2013.  On April 5, 2013, the Company refinanced its long-term debt.  The new long-term debt has a principal amount of $20 million which amortizes at an average monthly cost of approximately $289,000 through October 2016, as compared to approximately $950,000 in monthly debt cost prior to the refinance.

On May 16, 2013 at 11:00 a.m. PDT, Anthera Pharmaceuticals, Inc. will hold its annual shareholder meeting at 1204 Burlingame Avenue #8, Burlingame, CA  94010.  Prior to the meeting the Company encourages all shareholders to cast their votes on proposals presented in the proxy materials. Our Shareholder Letter, Annual Report for the fiscal year ended December 31, 2012, as well as our Proxy Statement for the annual shareholder meeting scheduled for May 16, 2013, are available free of charge on our website at www.anthera.com. Interested parties can request a copy free of charge by calling Investor Relations at 510-856-5600 or sending an e-mail request to Investor Relations by accessing our website (www.anthera.com), selecting the "Investors" tab and then selecting "Investor Contact." Please include your contact information with the request.

Following the annual shareholder meeting, the Company will host a conference call on May 20, 2013 at 2:
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Pharmaceuticals Announces Additional Data from Phase 2b PEARL-SC Blisibimod Study
2. Anthera Refinances Existing Debt with New $20 Million Credit Facility and Secures $18.5 Million Committed Equity Financing Facility
3. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
5. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
6. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
7. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
8. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
9. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
10. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
11. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
(Date:1/15/2014)... Jan. 15, 2014  In an unprecedented effort to curb the spread ... and other transport vehicles, an advanced and portable UV germicidal lamp ... the first time. In order to prevent EMS ... pathogens, West Palm Beach Fire Rescue is ...
(Date:1/15/2014)... Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® CGM System as a non-invasive, wireless continuous glucose ... , Executive Chairman and Interim CEO of Echo Therapeutics, ... Annual Equity Conference. Mr. Doman will ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading ... to release its second quarter 2011 financial results on Tuesday, ... financial markets.  The Company will also host a conference call ... 2011 to discuss its financial results and provide an update ...
... CHADDS FORD, Pa., June 30, 2011 Endo Pharmaceuticals (Nasdaq: ... phase 2 study comparing the novel investigational drug axomadol against ... chronic low back pain. The results indicate that axomadol did ... completing additional analyses of the data and evaluating the path ...
Cached Medicine Technology:Watson to Host Conference Call and Webcast to Discuss Second Quarter 2011 Earnings 2Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain 2
(Date:4/17/2014)... 17, 2014) Two recent papers by a ... colleagues may help scientists develop treatments or vaccines ... Japanese encephalitis and other disease-causing flaviviruses. , Jeffrey ... molecular genetics at the School of Medicine and ... Medical Institute, and colleagues recently published articles in ...
(Date:4/17/2014)... Le Bonheur Children,s Hospital Pediatrician-in-Chief Jon McCullers, MD, ... the April issue of Nature Reviews Microbiology ... Dr. McCullers, a world-renowned infectious disease specialist, ... the University of Tennessee Health Science Center, analyzed ... 1918, 1957 and 1968 pandemics, as well as ...
(Date:4/17/2014)... military personnel who served in Iraq and Afghanistan ... injury (TBI) were compared to military personnel without ... Differences in measures of overall disability, cognitive function, ... are reported in an article in Journal ... Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... as many as 10 million older Americans suffer from ... isolation. , However, new research a project that ... for six years found that Internet use among ... more than 30 percent. , "That,s a very strong ... of telecommunication, information studies and media who led the ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... love and addiction may go hand in hand due ... as a result of dopamine release// (neurotransmitter) after having ... of the effects observed following drug abuse with cocaine ... leaves the user with an insatiable feeling, probing for ...
... Cardiac rehabilitation program with safe and tolerable exercise can ... which help them to have a better heart function//. ... the supervision of Cardiologist, Jonathan Rhodes. ,The ... group of 8 to 17 with severe congenital heart ...
... the coffee cap proposed by a study by Florian Koppelstatter, ... cup of coffee with 100 mg caffeine can boost short-term ... 15 healthy men aged 26 to 47. Participants were tested ... consumed a placebo. 100 mg caffeine can be found in ...
... Austrian researchers at the annual meeting of the Radiological ... that caffeine has the ability to boost short-term memory// ... control this activity. ,Caffeine is normally found ... chocolate. The researchers tested 15 subjects who had just ...
... called Sonam was born with a hearing in both ears in ... completing her first year as result of a successful cochlear implant ... shortcoming when she was three months old. But they did not ... down the line, she behaves like any other normal child. ...
... Bill Gates, Chief of Microsoft, will visit India on 6 ... will be among the cities he will visit as he ... India//. ,India figures very high on the priority list ... him sharing his IT vision as he interacts with key ...
Cached Medicine News:Health News:Love And Drug Addiction Share The Same Chemistry 2Health News:Early Intervention Required For The Hearing Impaired 2Health News:Bill Gates Takes Personal Interest in AIDS Program 2
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
BioVintages Biotin-Trapper™ Streptavidin Magnetic Beads (1 mm - 2 mm) are designed for single-step capture of biotinylated molecules such as DNA, RNA or protein from cell lysates or hybridizatio...
... is a method for isolating antibodies, ... cells using affinity binding, while retaining ... on the particles to separate biotinylated ... the MagnaBind™ Beads from the suspension, ...
... m Dynabeads with covalently bound ... any biotinylated target. The Dynabeads® ... area, high capacity, magnetic pull ... during incubation. The MyOne™ products ...
Medicine Products: